Methods of treating disorders
AssigneeFoghorn Therapeutics Inc.
InventorsQianhe ZHOU, Michael BOCKER, Ho Man CHAN, Luis SOARES
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for the treatment of BAF-related disorders such as cancers and viral infections.
Claims67
A method of treating soft tissue sarcoma in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the sarcoma.
A method of reducing tumor growth of a soft tissue sarcoma in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the tumor.
A method of inducing apoptosis in a soft tissue sarcoma cell, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell.
A method of reducing the level and/or activity of SMARCD1 in a soft tissue sarcoma cell, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell.
A method of modulating the activity of an SS18-SSX fusion protein, SS18 wild-type protein, or SSX wild-type protein in a cell, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell.
A method of modulating the level and/or activity of an SS18-SSX fusion protein, SS18 wild-type protein, or SSX wild-type protein in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in a cell or subject.
A method of treating a disorder related to an SS18-SSX fusion protein, SS18 wild-type protein, or SSX wild-type protein in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in an SS18-SSX fusion protein-expressing cell in the subject.
A method of modulating the activity of a BAF complex in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A method of increasing the level and/or activity of BAF47 in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A method of decreasing Wnt/β-catenin signaling in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A method treating a disorder related to BAF47 in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the subject.
A method for treating cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in a cancer cell, wherein the cancer is a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, stomach cancer, breast cancer, B-cell acute lymphoblastic leukemia, multiple myeloma, or thyroid cancer.
A method of reducing tumor growth of a cancer in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in a tumor cell, wherein the cancer is a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, stomach cancer, breast cancer, B-cell acute lymphoblastic leukemia, multiple myeloma, or thyroid cancer.
A method of inducing apoptosis in a cancer cell, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell, wherein the cancer is a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, stomach cancer, breast cancer, B-cell acute lymphoblastic leukemia, multiple myeloma, or thyroid cancer.
A method of reducing the level and/or activity of SMARCD1 in a cancer cell, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell, wherein the cancer is a CD8+ T-cell lymphoma, endometrial carcinoma, ovarian carcinoma, bladder cancer, stomach cancer, pancreatic cancer, esophageal cancer, prostate cancer, renal cell carcinoma, melanoma, colorectal cancer, non-small cell lung cancer, stomach cancer, breast cancer, B-cell acute lymphoblastic leukemia, multiple myeloma, or thyroid cancer.
A method of modulating the activity of a SMARCD1 fusion protein in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A method of modulating the level and/or activity of a SMARCD1 fusion protein in a cell or subject, the method comprising contacting the cell with an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A method of treating a disorder related to a SMARCD1 fusion protein in a subject in need thereof, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in a SMARCD1 fusion protein-expressing cell.
A method of treating a viral infection, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in a cell of the subject.
A method of treating cancer in a subject determined to have an elevated level of SS18-SSX fusion protein, SS18 wild-type protein, SSX wild-type protein, or a SMARCD1 fusion protein, the method comprising administering to the subject an effective amount of an agent that reduces the level and/or activity of SMARCD1 in the cell or subject.
A composition comprising an adult soft tissue sarcoma cell and an agent that reduces the level and/or activity of SMARCD1 in a cell.
Dependencies are inferred from the claim text.